Optical Coherence Tomography Angiography Characteristics of Patients With Surgically Closed Full-thickness Idiopathic Macular Holes < 600 μm With Air Versus 10% SF6 Tamponade

Sponsor
Medical University of Graz (Other)
Overall Status
Recruiting
CT.gov ID
NCT05223205
Collaborator
(none)
40
1
2
26.3
1.5

Study Details

Study Description

Brief Summary

State of the art treatment for idiopathic macular holes consists of pars plana vitrectomy, internal limiting membrane staining with a blue colouring dye, internal limiting membrane peeling and filling of the vitrectomized space with a specific tamponade such as air and SF6. Air and SF6 have previously shown similar closure rates, although there was a trend towards lower closure rates in large diameter IMH (Idiopathic Macular Holes) using air. IMH with diameters < 600 μm are currently believed to have similar closure rates with air and SF6. The investigators want to assess possible effects of the used tamponade (air or SF6) on closure rates and perfusion parameters represented by OCTA (Optical coherence tomography angiography). IMH eyes with a minimum diameter > 600 μm will be excluded. Two idiopathic macular hole patient groups will therefore be formed: The first group (group 1) will receive air after vitrectomy and membrane peeling, the second group (group 2) will receive 10% SF6 (and 90% air) after vitrectomy and membrane peeling. After recruitment, patients will therefore be electronically randomized to one of the two groups. The groups will then be compared by the means of OCT (Optical coherence tomography) and OCTA.

Note: The trial was registered retrospectively on Clinicaltrials.gov after start of recruitment.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Air
  • Procedure: 10% SF6 and 90% air
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Optical Coherence Tomography Angiography (AngioVue™, Optovue Inc., Fremont, Calif., USA) Characteristics of Patients With Surgically Closed Full-thickness Idiopathic Macular Holes < 600 μm With Air Versus 10% SF6 Tamponade - a Pilot Study
Actual Study Start Date :
Jul 6, 2020
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Air group

Air tamponade after vitrectomy.

Procedure: Air
Test if air is sufficient for macular hole closure.

Experimental: SF6 group

10% SF6 tamponade after vitrectomy.

Procedure: 10% SF6 and 90% air
Test if 10% SF6 and 90% air is sufficient for macular hole closure.

Outcome Measures

Primary Outcome Measures

  1. Macular hole closure [2 weeks]

Secondary Outcome Measures

  1. Foveal avascular zone area [3 months]

  2. Parafoveal vessel density [3 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient must be able and willing to give informed consent.

  • Patient must be between 18 and 100 years of age.

  • Patient must not have any significant media opacity which interferes with the examination.

  • Patient must have an (stage 1-4) idiopathic macular hole requiring surgery.

Exclusion Criteria:
  • Unwilling or unable to provide informed consent

  • Under 18 or over 100 years of age

  • Significant media opacities

  • Systemic pathologies making an examination difficult or cumbersome to the patient

  • Primary and/or secondary epiretinal membranes (ERM), except incipient ERMs not affecting the foveal contour and not requiring surgery

  • Full-thickness idiopathic macular hole > 600 μm in minimum diameter

  • Nonclosure

  • Lamellar holes not requiring surgery

  • Pseudo holes

  • Glaucoma

  • Diabetes

  • Anisometropia > 2 diopters

  • High myopia (spherical equivalent > 6 diopters and/or axial length > 26 mm

  • Other retinal or ophthalmic pathologies except moderate cataract

  • OCTA scan signal strength < 5

  • Low image quality

  • Failure of automatic layer segmentation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Ophthalmology Graz Styria Austria 8036

Sponsors and Collaborators

  • Medical University of Graz

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Medical University of Graz
ClinicalTrials.gov Identifier:
NCT05223205
Other Study ID Numbers:
  • 32-465 ex 19/20
First Posted:
Feb 3, 2022
Last Update Posted:
Feb 22, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 22, 2022